A closely watched cardiovascular drug from Novartis, pelacarsen, has failed in a pivotal Phase 3 study, the HORIZON trial, marking a significant setback for the company and its efforts to address a prevalent heart disease risk factor, Lp(a). This failure was announced on Friday and has raised concerns within the pharmaceutical industry regarding the viability of targeting Lp(a) as a therapeutic approach.
Pelacarsen had previously demonstrated promising results in earlier trials by significantly lowering Lp(a) levels, which are associated with an increased risk of severe cardiovascular events. However, the recent trial results indicate that the drug did not achieve its primary endpoint of reducing cardiovascular death or events such as heart attacks and strokes when compared to a placebo.
This outcome not only impacts Novartis’ portfolio but also reflects broader challenges in the cardiovascular drug development landscape, potentially influencing future investments and research directions in this critical therapeutic area.
Open the full market picture for your next decision →
